Mixture of Mono-(2A-deoxy-2A-(2-carboxyethyl)thio)-altro-Sugammadex and Mono(3-deoxy-3-(2-carboxyethyl)thio)-Sugammadex

Product Description

Mixture of Mono-(2A-deoxy-2A-(2-carboxyethyl)thio)-altro-Sugammadex and Mono(3-deoxy-3-(2-carboxyethyl)thio)-Sugammadex
Catalog number: B2027399
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 mg
Molecular Weight or Concentration: NA
Supplied as: Chemicals
Storage: −80°C
Keywords: Sugammadex Regioisomers Mixture, Sugammadex Impurity Mixture, Mono-altro-Sugammadex Mixture

References:
1. Bom, A., Bradley, M., Cameron, K., Clark, J. K., Van Egmond, J., Feilden, H., … & Zhang, M. Q. (2002). A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic receptor. Angewandte Chemie International Edition, 41(2), 265-270.
2. Welliver, M. (2006). New drug survey: Sugammadex sodium, a selective relaxant binding agent. AANA Journal, 74(5), 357-363.
3. Nicholson, W. T., Sprung, J., & Jankowski, C. J. (2007). Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 27(8), 1181-1188.
4. Gijsenbergh, F., Ramael, S., Houwing, N., & van Iersel, T. (2005). First human exposure to Org 25969, a novel reversal agent in development for rapid reversal of rocuronium-induced neuromuscular block. Anesthesiology, 103(4), 711-717.
5. Naguib, M. (2007). Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesthesia & Analgesia, 104(3), 575-581.
6. Zhang, M. Q. (2012). Drug-specific cyclodextrins: the replacement of anticholinesterases by sugammadex. Chemistry–A European Journal, 18(7), 1858-1863.
7. Hunter, J. M., & Naguib, M. (2018). Sugammadex: the past, present and future. Anaesthesia, 73(S1), 58-63.
8. Suy, K., Morias, K., De Boer, H. D., Van Egmond, J., Heeringa, M., Booij, L. H., & Driessen, J. J. (2007). Effective reversal of moderate rocuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology, 106(2), 283-288.
9. De Boer, H. D., van Egmond, J., Driessen, J. J., & Booij, L. H. (2007). Time course of action of rocuronium 0.6 mg kg− 1 in combination with sugammadex 8.0 mg kg− 1. Anaesthesia, 62(1), 38-42.
10. Peeters, P., Passier, P., Smeets, J., Zwiers, A., de Zwart, M., van de Wetering-Krebbers, S., & van Iersel, T. (2010). Pharmacokinetics and safety of sugammadex in subjects with severe renal impairment. Anesthesiology, 113(5), 1100-1109.
Mixture of Mono-(2A-deoxy-2A-(2-carboxyethyl)thio)-altro-Sugammadex and Mono(3-deoxy-3-(2-carboxyethyl)thio)-Sugammadex

Products Related to Mixture of Mono-(2A-deoxy-2A-(2-carboxyethyl)thio)-altro-Sugammadex and Mono(3-deoxy-3-(2-carboxyethyl)thio)-Sugammadex can be found at Powder